针对心血管疾病中的CD8+T细胞:当前的选择和治疗前景
Rida Al-Rifai1,2, Vincent Duval1,2, Icia Santos-Zas3
1Université Paris Cité, INSERM U970, Paris Cardiovascular Research Center, 56 Rue Leblanc, 75015 Paris, France.
Cardiovascular research
|May 31, 2025
概括
反CD8单克隆抗体 (mAbs) 显示出治疗由过度活跃的细胞毒性T淋巴细胞驱动的疾病的希望. 临床前研究表明,它们有潜力限制组织损伤,为人体试验铺平了道路.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 治疗方法 治疗方法
背景情况:
- 细胞毒性T淋巴细胞 (CTLs),通过CD8核受体表达来识别,对于抗病毒和抗癌免疫是至关重要的.
- CD8存在各种形式,CD8αβ异构体是最常见的,对T细胞受体激活至关重要.
- CD8+ T 细胞功能的调节可以通过伊塔科纳酸和向单克隆抗体 (mAbs) 等药物来实现.
研究的目的:
- 探索抗CD8单克隆抗体 (mAbs) 对涉及过活化细胞毒性CD8+T细胞的疾病的治疗潜力.
- 在实验模型中研究抗CD8mAbs在缓解CD8+T细胞介导的组织损伤方面的有效性.
- 突出针对基于抗CD8 mAb的疗法的临床评估的准备.
主要方法:
- 在实验模型中使用抗CD8α或抗CD8β单克隆抗体 (mAbs) 来研究CD8+细胞功能.
- 使用免疫成像探针来预测癌症免疫治疗反应.
- 在临床前疾病模型中评估抗CD8耗尽mAbs的治疗效果.
主要成果:
- 实验模型表明,抗CD8耗尽mAbs可以显著减少由CD8+T细胞引起的组织损伤.
- 抗CD8mAbs正在研究用于治疗与T细胞过活化相关的急性,亚急性和慢性心血管疾病.
- 第一个治疗性抗CD8 mAb,PLG101的临床前开发正在推进.
结论:
- 抗CD8mAbs代表了一种有前途的治疗策略,用于特征为过度T细胞细胞分解活性的疾病.
- 在临床前模型中证明的疗效支持抗CD8 mAb疗法的临床转化.
- 需要进一步的研究和人体试验,以确定抗CD8mAbs在治疗免疫媒介疾病中的安全性和有效性.
关键词:
CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD9 CD8 CD8 CD8 CD8 CD9 CD8 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 是一个字体的字体的字体是什么意思心血管疾病的心血管疾病细胞毒性 细胞毒性炎症 炎症是一种炎症.淋巴细胞 淋巴细胞更多相关视频
相关概念视频
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Rheumatic Heart Disease III: Medical Management
290
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
290
Myocarditis III: Medical Management
178
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
178
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
453
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
453


